Free Trial

Akero Therapeutics Q2 2023 Earnings Report

Akero Therapeutics logo
$28.37 -0.97 (-3.31%)
(As of 05:45 PM ET)

Akero Therapeutics EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.61
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Akero Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Akero Therapeutics Announcement Details

Quarter
Q2 2023
Time
Q2 2023 Earnings Release
Your chance to get on the next “60-Second Trade” (Ad)

Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!

Just head over here!

Akero Therapeutics Earnings Headlines

Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Akero Therapeutics initiated with a Buy at Citi
Akero Therapeutics (AKRO) Receives a Buy from Phillip Securities
See More Akero Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akero Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akero Therapeutics and other key companies, straight to your email.

About Akero Therapeutics

Akero Therapeutics (NASDAQ:AKRO), together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

View Akero Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings